Left ventricular (LV) systolic function is a known prognostic factor after ST-segment elevation myocardial infarction (STEMI). We evaluated the prognostic value of LV global longitudinal strain (GLS) in patients with chronic obstructive pulmonary disease (COPD) after STEMI. 
Introduction
Patients with chronic obstructive pulmonary disease (COPD) have an increased risk of hospitalization and death due to cardiovascular diseases. 1 Particularly, among patients with ST-segment elevation myocardial infarction (STEMI), the presence of COPD has been independently associated with higher mortality when compared with patients without COPD. [2] [3] [4] The underlying factors explaining this mortality difference include delayed diagnosis and reperfusion treatment of a STEMI and underuse of secondary prevention therapy. 5 These may lead to large left ventricular (LV) infarct size and adverse remodelling (dilation) during follow-up, increasing the risk of heart failure and cardiovascular mortality. Left ventricular ejection fraction (LVEF) is frequently used in clinical practice as a marker of the myocardial damage (infarct size) after STEMI and is a well-known prognostic determinant. However, in a recent large cohort of STEMI patients, COPD patients had comparable LVEF as patients without COPD. 6 Two-dimensional (2D) speckle tracking echocardiography is an advanced technique to assess myocardial deformation. In contrast to LVEF which reflects a change in LV volume, 2D speckle tracking echocardiography evaluates the active contraction of the myocardium reflecting directly the myocardial function. LV global longitudinal strain (GLS) measured with 2D speckle tracking echocardiography is currently one of the most frequent variables to reflect LV systolic function and has been associated with prognosis after STEMI. 7 In contrast to LVEF, LV GLS showed that STEMI patients with COPD had larger myocardial damage than patients without. 6 Therefore, LV GLS may have more discriminative power than LVEF to identify the patients with increased mortality risk after STEMI. The present study evaluated the prognostic value of LV GLS in STEMI patients with COPD and investigated whether LV GLS has incremental value over conventional echocardiographic parameters for LV systolic function.
Methods Patient population and data collection
From an ongoing registry of patients admitted with acute STEMI and treated with primary percutaneous coronary intervention at the Leiden University Medical Center (Leiden, the Netherlands) between 2004 and 2013, patients with COPD were identified. When pulmonary function tests were available, COPD was defined according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines (ratio of forced expiratory volume in 1 s to forced vital capacity <0.7). 8 Otherwise, a documented history of COPD was taken into consideration. Patients were treated according to the guideline based institutional STEMI protocol (MISSION!) as described previously. [9] [10] [11] Optimal medical therapy was initiated during hospitalization and echocardiography was performed within 48 h of admission. Clinical and echocardiographic data were collected prospectively in the departmental Cardiology information system (EPD-vision) and echocardiographic database, respectively. All data were retrospectively analysed. For this retrospective analysis, the Institutional Review Board waved the need for patient written informed consent. Patients were excluded, if they had a documented history of asthma, when the echocardiographic image quality was not suitable for LV GLS measurement using 2D speckle tracking echocardiography or when patients died before echocardiography was performed.
Clinical data
Demographic and clinical characteristics were recorded. Diabetes mellitus was defined as having a history of diabetes mellitus and subsequent medical therapy with insulin, oral glucose-lowering drugs, or diet. Hypertension was defined as previous use of antihypertensive medication or a systolic blood pressure of >140 mmHg and/or diastolic blood pressure of >90 mmHg. 12 Hypercholesterolemia was defined as having a documented history of hypercholesterolemia and/or statin use. During invasive coronary angiography, the culprit vessel was identified and multivessel disease was defined as more than one vessel with >50% luminal stenosis.
Transthoracic echocardiography
Images were obtained using a commercially available system (Vivid 7 and E9, GE Healthcare, Horten, Norway) with the patient at rest, in left lateral decubitus position. A 3.5 MHz or M5S transducer was used to obtain parasternal, apical, and subcostal views and images were digitally stored in cine-loop format. Standard 2D, M-mode, colour, pulsed-, and continuous-wave Doppler images were acquired according to the recommendations by the American Society of Echocardiography. 13 Data analysis was performed off-line using the EchoPac software (version BT13, GE Medical Systems, Horten, Norway). LV dimensions were measured in the parasternal long-axis view and LV mass was calculated using the Devereux's formula. 13 In apical two-and four -chamber views, LV volumes were measured and LVEF was calculated using the biplane Simpson's method. 13 Furthermore, the LV was divided into 16 segments for calculation of the wall motion score index (WMSI). Each individual segment was scored based on systolic thickening and motion (1 = normokinesia, 2 = hypokinesia, 3 = akinesia, and 4 = dyskinesia). 13 Subsequently, the WMSI was calculated as the sum of all individual segments divided by the number of segments. 13 LV diastolic function was assessed by obtaining peak early (E) and late (A) diastolic velocities and E-wave deceleration time on pulsed-wave Doppler recordings of the transmitral flow. 14 LV filling pressures were evaluated by calculating the E/e' ratio using the average e', measured at both the septal and lateral side of the mitral annulus with tissue Doppler imaging at the apical four-chamber view. 14 To assess global right ventricular (RV) systolic function, tricuspid annular plane systolic excursion (TAPSE) according to current recommendations. 13 The systolic pulmonary arterial pressure (SPAP) was estimated by calculating the RV pressure from the peak velocity of the tricuspid regurgitant jet according to the Bernoulli equation and adding the right atrial pressure. 13 The right atrial pressure was determined according to the diameter and inspiratory collapse of the inferior vena cava.
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2D speckle tracking echocardiography
Analysis of transthoracic echocardiography by 2D speckle tracking echocardiography was performed offline and blinded to clinical data. To quantify LV GLS, standard routine grey-scale images were used from the apical two-, three-, and four-chamber views, with a frame rate > _40 frames/s. The LV endocardial border was traced at end-systole at the three apical views, and the automatically created region of interest was manually adjusted to the thickness of the myocardium. Subsequently, the myocardium was tracked throughout the cardiac cycle and segments with poor tracking were (manually) excluded. LV GLS was provided by the software as the average peak systolic strain of the three apical views and presented in a 17-segment 'bull's eye' plot. 15 To correct for the potential effect of the RV pressure overload secondary to COPD on the myocardial strain of the septal segments and subsequently on the LV GLS, the average of regional longitudinal strain of five septal segments was calculated ( Figure 1 ). The value of longitudinal strain of the remaining segments was averaged and compared with the average value of the septal segments. Intra-and inter-observer variability of LV GLS analysis in our laboratory have been previously reported. Follow-up and endpoint definitions
Patients were followed at the outpatient clinic according to the institutional care track protocol. 9 The occurrence of adverse events (all-cause mortality and heart failure hospitalization) at long-term follow-up was prospectively recorded through telephone interviews and requesting medical records when indicated. Data on mortality was collected through municipal civil registries, which contain up-to-date mortality data. Allcause mortality was the primary endpoint. The secondary endpoint was a composite of all-cause mortality and heart failure hospitalization. Heart failure hospitalization was defined as hospitalization for new-onset or worsening of heart failure. Follow-up was obtained for all study patients.
Statistical analysis
Categorical data are presented as frequencies and percentages. Continuous data are presented as mean ± standard deviation or median and interquartile range, as appropriate. Furthermore, Kaplan-Meier analysis was performed for survival and cumulative event rates. For the combined endpoint, patients were censored at the occurrence of the first event. The study population was divided into two groups according to the median LV GLS (-14.4%) and the cumulative event rates were compared with log-rank tests.
Finally, the association of clinical and echocardiographic variables with the primary and secondary endpoints were tested using the Cox proportional hazards analysis. The hazard ratio and 95% confidence interval were calculated. Due to the relatively small number of events, the number of covariates added into the multivariate models was adjusted to avoid overfitting. Clinically relevant and/or statistically significant predictors in the univariable Cox regression analysis (P < _ 0.05) were included in multivariable models. The final multivariable model for the primary endpoint consisted of clinical (age, diabetes, and b-blocker use) and echocardiographic variables of LV and RV systolic function (TAPSE, LVEF, WMSI, and LV GLS). For the secondary endpoint, the same clinical variables were used and E/e' ratio was added to the echocardiographic parameters. To evaluate the incremental value of LV GLS over clinical and conventional echocardiographic variables, nested regression models were created and the change in global v 2 values was calculated. A twosided P-value of <0.05 was statistically significant. All statistical analyses were performed using SPSS software (version 24, IBM SPSS statistics for Windows, Armonk, NY, USA).
Results
Of 173 STEMI patients with COPD treated with primary percutaneous coronary intervention, 30 patients were excluded due to transfers to other hospitals before echocardiography was performed (n = 20), death within 48 h (n = 2) or LV GLS measurement not feasible due to image quality (n = 8) (Figure 2) . Therefore, the total study population consisted of 143 consecutive patients (mean age 70 ± 11 years, 71% male). Segmental strain analysis was feasible in 131 out of 143 (92%) study patients due to variation in heart rate or frame rate between the three apical views. After a median follow-up of 68 (interquartile range 38. Hypercholesterolemia, n (%) 31 (22) 16 (22) 15 (23) 0.837
Peripheral vascular disease, n (%) 13 (9) 4 (5) 9 (14) 0.080 Previous myocardial infarction, n (%)
14 (10) 5 (7) 9 (14) 0.152
Killip class > _2, n (%) 12 (8) 3 (4) 
Clinical characteristics
Baseline clinical characteristics are reported in Table 1 for the total study population, survivors and non-survivors. Almost half of the patients (53%) had multivessel disease and the right coronary artery was the most frequently involved culprit vessel (40%). One-fifth of the population had impaired renal function (estimated glomerular filtration rate <60 ml/min/1.73 m 2 ). Nearly all patients received the medication as recommended by the most recent European Society of Cardiology STEMI guidelines, except for b-blockers which were prescribed in 85% of the patients.
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When comparing survivors vs. non-survivors, patients who died were significantly older (74 ± 10 vs. 66 ± 10 years; P < 0.001), more often diabetics (21% vs. 7%; P = 0.010), had a slightly lower diastolic blood pressure (80 ± 19 vs. 87 ± 15 mmHg; P = 0.011) and less frequent prescription of b-blockers after discharge (82% vs. 95%; P = 0.017), when compared with survivors.
Echocardiographic characteristics
Baseline echocardiographic characteristics for the total study population, survivors and non-survivors are reported in Table 2 . In the total study population, mean LVEF and LV GLS were 46 ± 10% and -13.8 ± 4.0%, respectively. Mean LV filling pressures were increased (E/e' ratio 15.7 ± 7.8).
Patients who died had a significantly lower LVEF and more impaired LV GLS shortly after myocardial infarction (43 ± 9 vs. 48 ± 9%; P = 0.001 and -12.9 ± 4.3 vs. -14.6 ± 3.4%; P = 0.011, respectively) when compared with the patients who survived. Furthermore, patients who died had higher LV filling pressures (E/e' ratio 17.5 ± 9.5 vs. 14.3 ± 5.6; P = 0.021). The segmental analysis showed that longitudinal strain values of both septal and non-septal segments were more impaired in patients who died as compared to survivors ( Table 2 ). There were no differences in SPAP between the groups. Patients who died had a significantly lower TAPSE compared with survivors (16.9 ± 4.6 vs. 18.5 ± 3.4 mm; P = 0.020), although the values were within normal ranges.
Survival analysis
Kaplan-Meier curves for all-cause mortality are shown in Figure 3A , with the population divided into two groups by the median LV GLS (-14.4%). The cumulative survival rates at 5 years were significantly lower for patients with LV GLS >-14.4% (more impaired) as compared to patients with LV GLS < _-14.4% (52% vs. 78%, log-rank; P = 0.004).
Similarly, the 5-year cumulative event-free survival rates for the combined endpoint (all-cause mortality and heart failure hospitalization) were significantly lower for patients with LV GLS >-14.4% (more impaired) when compared with patients with LV GLS < _-14.4% (50% vs. 80%, log-rank P = 0.001; Figure 3B) Table 3 summarizes the significant univariable associates of all-cause mortality and the combined endpoint (all-cause mortality and heart failure hospitalization). Age, diabetes, b-blocker use, TAPSE, LVEF, WMSI and LV GLS >-14.4% were introduced into a multivariable model to identify independent associates of all-cause mortality. The correlation coefficient for LV GLS and LVEF was 0.484, for LV GLS and WMSI, 0.445 and for LVEF and WMSI, 0.535 (P < 0.001 for all). Therefore, no evidence of multicollinearity was found and these variables could be introduced into the same multivariable model. Age, diabetes, and LV GLS >-14.4% were independently associated with all-cause mortality ( Table 3 ).
Prognostic value of LV GLS in COPD patients after STEMI
In addition, to identify independent associates of the combined endpoint, age, diabetes, b-blocker use, E/e' ratio, TAPSE, LVEF, WMSI and LV GLS >-14.4% were introduced into multivariable analysis. Only age and LV GLS >-14.4% were independently associated with the combined endpoint ( Table 3) .
LV GLS had incremental prognostic value as demonstrated by a significant increase of global v 2 to a model containing clinical and conventional echocardiographic parameters for both RV and LV systolic function ( Figure 4) .
Discussion
The present study demonstrates that in STEMI patients with COPD an impaired LV GLS is independently associated with worse long-term prognosis. Furthermore, LV GLS has incremental prognostic value over LVEF. This suggests that, in this specific patient population, LV GLS is more sensitive than LVEF to identify patients at risk for adverse events.
Prognosis of COPD patients after STEMI
Mortality rates are higher in patients with COPD after acute myocardial infarction as compared to patients without COPD. 2, 16 The higher mortality rates are frequently ascribed to the delayed diagnosis and reperfusion therapy of acute myocardial infarction. 5 Furthermore, underuse of b-blockers in COPD patients, due to the fear of bronchoconstriction, has been related to the higher mortality rates. 5, 17 However, data from the Valsartan in Acute Myocardial Infarction Trial (VALIANT) comparing 1258 COPD patients with 13 445 non-COPD patients showed a 14% increased risk of mortality after myocardial infarction among COPD patients, irrespective of b-blocker use. 4 The present study showed that the underuse of b-blockers was associated with worse outcomes. However, after correcting for other variables such as age, diabetes and LV GLS, b-blockers use was not independently associated with all-cause mortality or the combined endpoint. This suggests that LV myocardial damage, as reflected by more impaired LV GLS, is a stronger prognostic determinant than b-blocker use.
Prognostic importance of GLS vs. LVEF after STEMI
Echocardiographic assessment of infarct size has frequently relied on LVEF and WMSI. 18, 19 More recently, LV GLS has emerged as a good surrogate of myocardial infarct size 20, 21 and has incremental prognostic value over LVEF in the general population. 7 In STEMI patients with COPD, LV GLS has shown to be more sensitive than LVEF to evaluate the extent of myocardial damage. 6 In a retrospective series including 133 COPD patients and 1617 patients without COPD, cardiac biomarkers and conventional echocardiographic parameters of infarct size (LVEF and WMSI) were similar in both groups whereas LV GLS was significantly more impaired in COPD patients as compared with patients without COPD. 6 Therefore, evaluation of LV GLS might be sensitive to detect myocardial damage after STEMI in patients with COPD. It has been shown that the chronic inflammatory-catabolic state of COPD patients may be the underlying pathophysiology explaining the larger myocardial damage in these patients. 22 Increased levels of pro-inflammatory mediators and oxidative stress are recognized in COPD patients, and have also been associated with reperfusion injury, leading to increased myocardial damage even shortly after myocardial infarction. 23, 24 Furthermore, patients with COPD exhibit increased circulating levels of matrix metalloproteinases, which have been involved in the pulmonary remodelling process as well as in the status due to the release to the systemic circulation of interleukins (IL-6 and IL-8), tumour necrosis factor-a, and C-reactive protein, increased oxidative stress and increase of proteases involved in the remodelling process of the vasculature and myocardium. These factors accelerate the atherosclerosis process, increasing the risk of myocardial infarction. During myocardial infarction, these factors also may increase the risk of reperfusion injury, and at follow-up, may influence the LV remodelling process leading to heart failure.
LV remodelling after myocardial infarction. 25, 26 Figure 5 demonstrates a schematic overview of the association between systemic inflammation in COPD patients and the occurrence and consequences of STEMI. Parallel to chronic inflammation resulting in cardiac remodelling, COPD is characterized by hypoxia causing increased pulmonary vascular resistance. 27 This increase in pulmonary vascular resistance can lead to an increase in pulmonary arterial pressures and subsequent RV dysfunction. This phenomenon has even been described in patients with mild COPD. 28 In our patient cohort, SPAP, and RV function (using TAPSE) were evaluated with echocardiography, showing that TAPSE was significantly associated with all-cause mortality. However, after correcting for various factors, RV function was not independently associated with mortality. Interestingly, LV GLS did have a significant prognostic association with both endpoints, even after correction for RV function. This is the first study evaluating the prognostic implications of LV GLS, and its incremental prognostic value over conventional parameters such as TAPSE, LVEF, and WMSI in STEMI patients with COPD. Patients with an LV GLS >-14.4% had significantly worse outcome than patients with LV GLS < _-14.4%. These findings suggest that, LV GLS might be a more sensitive marker to identify the COPD patients at the highest risk of adverse events at the moment of discharge after STEMI, than the conventional LVEF.
Study limitations
Several study limitations should be acknowledged. This is a single centre, retrospective study limiting generalizability of the results. Furthermore, pulmonary function tests were not available for every patient to confirm the COPD status as stated in medical records. Therefore, we could not assess differences between patients with different GOLD stages. However, previous studies have used the same definition of COPD in the absence of structural testing of pulmonary function in day to day practice.
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Conclusion
In STEMI patients with concomitant COPD, impaired LV GLS is independently associated with worse long-term prognosis. Importantly, LV GLS has incremental prognostic value over established risk factors and LVEF. A 28-year-old man, who was diagnosed with hypertrophic cardiomyopathy (HCM) 3 years previously (Panel A and Supplementary data online, Video S1), was admitted due to cardiac arrest, while walking towards his workplace. His electrocardiogram repeatedly showed ventricular fibrillation/tachycardia, despite several electrical defibrillations. Therefore, he was treated pharmacologically (bisoprolol and nifekalant) and with mechanical cardiopulmonary support. His cardiopulmonary status was stabilized without any neurological deficits after 2 weeks. However, his echocardiogram on Day 40 revealed the marked thinning of basal interventricular septum (Panel C and Supplementary data online, Video S3; an arrow), which was not noted 30 days previously (Panel B and Supplementary data online, Video S2). The diagnostic workup was re-conducted for possible secondary cardiomyopathies. His angiotensin-converting enzyme was within the normal range (8.3 U/L); however, the serum interleukin-2 receptor level was elevated (532 U/mL). Cardiac magnetic resonance imaging with gadolinium injection revealed late enhancement of the basal interventricular septum (Panel D). Furthermore, the positron-emission tomography/computed tomography demonstrated high uptake in the basal interventricular septum of the heart, but nowhere else in other organs (Panel E). Although endomyocardial biopsy was not diagnostic, a definitive diagnosis of isolated cardiac sarcoidosis was made. Immunosuppressive therapy was initiated: steroid pulse treatment for 3 days followed by oral prednisone, gradually diminished from 30 mg to 5 mg daily in 6 months. The treatment course was uneventful and without relapses (Panel F).
IMAGE FOCUS
Cardiac sarcoidosis may result in asymmetric septal hypertrophy, which is more common in HCM. The structural transition of cardiac sarcoid spectrum from the 'hypertrophic' to the thin stage has been rarely documented.
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